ANN ARBOR, Mich., – September 16, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces an advance conference call advisory for all shareholders and other interested parties.

The Company plans to host a conference call for the purpose of updating shareholders on production, scientific milestones, commercialization strategy and other corporate developments.  The call will be hosted by Kraig’s founder and CEO, Kim Thompson and is planned for late October, pending the travel schedule of Thompson and members of the Kraig Labs team.

The Company plans on releasing definitive details, including call-in details, time and format, at least one week prior to conference call and shareholders are invited to submit questions to ir@kraiglabs.com.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

New corporate office in Ann Arbor gives Kraig Labs greater access to expert workforce and capacity for growth

Ann Arbor, Mich., –September 1, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that the Company have moved its corporate headquarters to a new location in Ann Arbor, Michigan.

The address of the new location is 2723 South State St., Suite 150 Ann Arbor, MI 48104.  The new phone number will be 734-619-8066.  All other contact information will remain the same.

“We are pleased to announce today that Kraig Labs has moved our corporate office to Ann Arbor.  Ann Arbor has an exceptional history of developing and attracting some of the brightest minds and most transformative companies in genetic engineering,” said Founder and CEO Kim Thompson.  “This move gives us increased access to a talented pool of scientists and technicians with a strong culture of innovation.  We look forward to continued growth of Kraig Labs and I believe this new headquarters and its access to a high skilled workforce will play an important role in that progress.”

“Companies like Kraig Labs know that this region’s talented workforce is a competitive advantage,” said Paul Krutko, president and CEO of Ann Arbor SPARK. “The strong cluster of biotech and life science companies in Ann Arbor attracts and nurtures businesses like Kraig Labs, which in turn cultivates the talent pool here. It’s exciting to welcome this growing business to the region.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories expands intellectual property protection of its transgenic silkworms and recombinant spider silk technology

LANSING, Mich., – August 19, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced that it, with the University of Notre Dame, filed two additional patents to strengthen its intellectual property protection surrounding its transgenic silkworms and spider silk technologies.

These patent applications are designed to protect the creation of the Kraig Labs transgenic silkworms and the resultant chimeric spider silk.  The Company currently has open patent actions in 10 countries, including key silk producer and consumer nations.

“From our inception, Kraig Labs has remained dedicated to a spirit of innovation and refused to accept can’t as an answer,” said Company Founder and CEO, Kim Thompson.  “This pursuit of the seemingly impossible led to a series of first of its kind inventions, including our recently announced Dragon Silk™ genetic line.  The filling of these two additional patents seeks to protect the creativity and value of that work for Kraig Labs and our shareholders, and goes hand in hand with our commercial market development plans.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Dear Shareholders,

In the coming month we will be moving our corporate office, from our location for the last nine years, at 120N Washington Sq., Lansing, Michigan, as the building is being repurposed.   We are taking this opportunity to find a location that better matches our growth plans for Kraig Labs.

Over and above notifying you of our pending move, we would also like to take a moment to provide some additional information on the status of our research and material development efforts.

Big Red

Big Red continues as one of our primary recombinant spider silk gene lines.  Similar to our recently announced Dragon Silk^TM line, Big Red is specifically designed to have a tensile strength significantly higher than conventional silk.  Designed specifically for increased strength with lower elasticity, the Big Red silk line we’ve created remains the ideal material for applications where excessive elasticity would decrease overall performance.   As we expand our research and rearing operation we expect that Big Red will be a significant element of that effort.

Laboratory lease

In 2011, we began renting additional laboratory space, at the Innovation Park in South Bend, Indiana.  This space was initially intended to provide a secondary location and overflow capacity for the work conducted in the laboratory at Notre Dame, our research center.  The decision to end the long running lease for this second lab was made after review and determining that we could expand our core research by focusing more of our attention into the Notre Dame lab.  By redirecting those resources we are increasing the number of microinjection and incorporate additional gene splicing technologies to further advance our market leading recombinant silk technology.  The increased scope and funding level for our collaborative research project signed in March, of this year, points to that refocus.  This initiative helped to promote our research efforts in developing new plasmids, new rounds of microinjections, and incorporating new gene splicing techniques.

Warwick Mill

Through our partnership with Warwick Mills we continue to make progress in developing new woven and knitted materials using our recombinant fiber technologies.  Over the last several months we have engaged with Warwick Mill on an initiative to produce a new material, we believe we will be able to announce the exciting details of that project in the fourth quarter of this year.  Warwick Mills remains an important element of our transition from a technology development company into a product delivery company.

We are proud of the technical team’s developments and partners’ progress.  We are excited about our results in the lab and pleased with how our business model is evolving.

Laboratory breakthrough results in Kraig Biocraft Laboratories’ strongest and most flexible recombinant spider silk technology.

LANSING, Mich., – June 29, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced the creation of Dragon Silk^TM, its strongest and most flexible recombinant spider silk technology.

Dragon Silk^TM represents a leap in the Company’s recombinant spider silk technology, combining both the elasticity and strength elements of native spider silk.  A small number of Dragon Silk^TM samples have demonstrated tensile strength as high as 1.79 gigapascals, exceeding widely reported spider silk strength (by as much as 37%, depending on source literature).  Several samples of Dragon Silk^TM also demonstrated elasticity above 38%, exceeding native dragline spider silk.  This new material has shown it can be more flexible than Monster Silk^® and stronger than Big Red, the Company’s leading recombinant spider silk products. The Company is now working to standardize the performance level across the entire Dragon Silk^TM genetic line.

“Dragon Silk^TM is our strongest and most flexible recombinant spider silk material to date,” said Company Founder and CEO Kim Thompson.  “We have never believed that native spider silk is the limit of strength and flexibility performance.  A few superstar individuals, within the genetically engineered colony we call Dragon Silk^TM, have demonstrated that extremely high level of performance in the laboratory.  We are now working to obtain that standard throughout the Dragon Silk^TM line.  Even as we undertake that work, our research team is working in parallel to create even more powerful transgenics. Dragon Silk^TM represents yet another material science breakthrough and shifts the standard of performance expectation for spider silk technologies.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Successful series of meetings with central and regional governments in Vietnam culminate in MOU and lay foundation for transgenic research and production.

LANSING, Mich., – June 15, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces that after a series of meetings with Vietnam’s central and regional governments, the Company has signed a memorandum of understanding (MOU).  This MOU outlines a framework for the creation and rearing of transgenic silkworms in Vietnam.  Pursuant to the MOU, Kraig Labs and the Vietnamese provincial government will jointly develop a cooperative plan for the development and production of Kraig Labs trangenics in Vietnam.

“This MOU represents a breakthrough for Kraig Labs and potentially the silk industry.  The Central and Provincial Government officials in Vietnam with whom we have held extensive meetings share our passion and vision for reinvigorating the silk industry.  This new relationship should bring new opportunities for both the Company and Vietnam.  The goal is commercialization of our disruptive technology for the technical textile markets,” said Company CEO Kim Thompson.  “Vietnam offers specialized silk infrastructure which is ideal for expanding our operations.  Vietnam’s tradition of quality silk production makes it an excellent fit for our transgenic silkworms.  This cooperative effort will further serve to support our recombinant silk technology, its many applications and end markets.”

The Company is continuing to work with the provincial government to develop advanced research and development facilities in Vietnam, as well as pilot production of transgenic hybrids.  Negotiations for a final agreement incorporating the terms of the MOU are expected to conclude in the third quarter of 2015.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

LANSING, Mich., – June 9, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, has provided a business update to shareholders via e-mail.  The content of the e-mail message is as follows:

Dear Shareholders,

As the past several months have been very busy and productive, I would like to highlight several achievements that have advanced the Company’s short-term and long-term position.

First, let me begin by thanking all of you for your patience during the past eight months.  As you may be aware, on June 5, 2015, the SEC declared our registration statement with Calm Seas Capital effective.  This registration secures up to $7.5 million, assuming all conditions are met, over the next 2 years to support the continued growth of our research, development, and production capacity.   As a small fully reporting company, we take the quiet period during the registration process very serious, but understand that the silence can be frustrating for our shareholders. However, by ensuring full compliance with the quiet period, which is required by federal securities laws, the Company and our shareholders are more fully protected during the registration process.  As the registration statement is now effective, the quiet period is over and we can once again communicate more regularly with our shareholders and the investing public at large.

Second, we have signed a new cooperative research and development agreement with the University of Notre Dame, which has accelerated the pace of development of our transgenic silkworm technology.  The additional resources we have allocated are designed to allow us to develop new and more powerful transgenic silkworm strains using the latest in genetic engineering technologies.  We believe this will allow us to produce even stronger and more flexible fibers.  As early testing of these new materials has shown promising results, we look forward to releasing additional details as they become available.

Furthermore, our pilot scale production facility recently delivered a batch of finished material and continues to produce Monster Silk^TM for use and evaluation.  These materials are a key element in fiber technology and performance evaluation for our potential market channel partners.  Of equal importance, this facility provides validation that the transition from laboratory scale to production can be completed for Big Red and future transgenic lines that we produce.  We anticipate significant growth in the capacity and proficiency of our silk production operations moving forward.

I am excited to announce the new Kraig’s quarterly newsletter- Spider Sense- which we will release at the end of each fiscal quarter beginning in July, 2015.  This newsletter will allow us to consistently share the Company’s progress with you.  The newsletter will be distributed via the Company website and opt-in emails.  Please sign up at https://www.kraiglabs.com/contact/ .

Our management remains focused on the Company’s underlying business as well as identifying and pursuing strategic opportunities to increase shareholder value.  The Company has been very impressed with the performance of our new COO, Jon Rice, who has been a powerful addition to our team and we expect great things from him in the second half of 2015.  We anticipate releasing further news regarding our business in the very near future.

In conclusion, my expectation for 2015 will be new opportunities that will serve to benefit all who are connected to the success of Kraig Biocraft Laboratories. We appreciate the commitment you, our shareholders, have made and continue to make supporting the Company.  On behalf of the entire Kraig Labs Team, thank you for sharing in our success and being a partner in our future.

Sincerely,

Kim K. Thompson
Chief Executive Officer, Chairman of the Board
About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

IR@kraiglabs.com

LANSING, Mich., –April 30^th, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that it has retained the New York law firm of Hunter Taubman Fischer LLC as legal counsel for all securities related matters.

“We are happy to announce that Hunter Taubman Fischer LLC will be representing the Company for SEC filings, compliance and general securities related matters” said Company founder and CEO Kim Thompson.  “We are very pleased to be in a position to make this appointment as we strengthen our management support team.  Hunter Taubman Fischer LLC has a proven track record for supporting a growing business such as ours.  We believe that the addition of Hunter Taubman Fischer LLC to the Kraig labs team will help improve our communications with both regulators and the investment community.   This move is a planned component of our future growth plans.  Their reputation for delivering outstanding client support in the areas of securities law and mergers & acquisitions was a key element of our decision.  We look forward to working with them as we institute our plans to expand Kraig Labs operations.”

The law firm of Hunter Taubman Fischer LLC (HTF) possess a broad base of knowledge and extensive experience in the areas of securities and mergers & acquisitions.  As a result of the global nature of HTF’s practice, they have attorneys fluent in English, Spanish, Portuguese, Mandarin and Cantonese.  They serve a wide range of public companies, focused on growth, trading on the NASDAQ, and NYSE. HTF will serve as the primary interface for Kraig Labs SEC communications and filings, with the goal of improving both the speed and effectiveness of all future filings.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass.

These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Labs strengthens management team, appointing new Chief Operations Officer with strong product development and commercialization experience

LANSING, Mich., –January 21, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces Jon Rice as the new Chief Operations Officer effective immediately.    Jon joins Kraig from Ultra Electronics (AMI) where he was responsible for all new product development and commercialization.  While at Ultra, Jon lead the development of advanced technologies for the US and global defense markets. In his new role he will provide direction for the commercialization of Kraig labs technologies including MonsterSilk^TM.

“Kraig Labs’ spider silk technology is the perfect fit for my passion and background in transitioning powerful, disruptive technologies.  Spider Silk is a product with tremendous potential and I’m honored to join a team so dedicated to seeing that vision realized.  The opportunity to be a part of the commercialization of this technology was an opportunity I could not pass up,” said Rice.

As COO Jon will be reporting directly to the Company CEO, Kim Thompson.  “We are excited that the Company has reached the point in its growth that it can bring in someone of Jon’s caliber.  He brings a proven track record of successfully transitioning products from development through to viable commercial products.  Jon will play an instrumental role in scaling up our production capacity and leading the growth of Kraig Labs.  We recruited Jon after an extensive search for a candidate we believed could make a real difference in our efforts to bring our products to market.  As part of our search we reviewed more than 1200 resumes from candidates coming out of the nation’s top MBA schools.  Jon was chosen because of his stellar track record, his experience in product development and commercialization, and his keen intellect and business drive.  His unique blend of business and technical acumen make him a great addition to our team,” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Internationale Textilmaschinen Ausstellung recognizes Kraig in “Most innovative small company” and “Best innovation – Agrotextiles” Classifications

LANSING, Mich., — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that the Company was named finalist in two categories for Internationale Textilmaschinen Ausstellung’s (“ITMA”) Future Materials Awards 2014.

“I would like to thank ITMA, the world’s largest international textile machinery exhibition, for recognizing our technology and efforts, and congratulate the other finalists for making the shortlist.  I believe that the recognition in the ‘Most innovative small company’ and ‘Best innovation, Agrotextiles’ categories is a testament to our team, our technology and our shareholders,” said Kraig CEO and founder, Kim K. Thompson.

Further ITMA Future Materials Awards 2014 information can be viewed at the following link: www.futurematerialsawards.com

Finalists can be viewed at the following link: www.futurematerialsawards.com/finalists.html

Further ITMA information can be viewed at the following link: www.cematex.com/whatisitma.cfm

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com